Truist Financial Downgrades Nuvalent (NASDAQ:NUVL) to Hold

Nuvalent (NASDAQ:NUVL) was downgraded by stock analysts at Truist Financial from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

A number of other research analysts have also recently commented on NUVL. Robert W. Baird set a $122.85 price target on Nuvalent in a report on Tuesday. Raymond James Financial cut Nuvalent from an “outperform” rating to a “market perform” rating in a report on Tuesday. Cantor Fitzgerald cut Nuvalent from an “overweight” rating to a “neutral” rating in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvalent in a report on Tuesday, April 21st. Finally, Leerink Partners set a $165.00 price target on Nuvalent in a report on Wednesday, June 3rd. Five equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $131.15.

Nuvalent Stock Up 0.1%

NUVL stock opened at $123.35 on Tuesday. Nuvalent has a twelve month low of $71.13 and a twelve month high of $123.62. The stock has a market cap of $9.74 billion, a P/E ratio of -20.35 and a beta of 1.15. The business’s 50-day moving average price is $103.44 and its 200-day moving average price is $103.19.

Nuvalent (NASDAQ:NUVL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same quarter in the previous year, the firm earned ($1.18) earnings per share. On average, equities research analysts expect that Nuvalent will post -5.74 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Deborah Ann Miller sold 5,500 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $107.84, for a total value of $593,120.00. Following the transaction, the insider directly owned 59,634 shares of the company’s stock, valued at approximately $6,430,930.56. The trade was a 8.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Alexandra Balcom sold 11,430 shares of Nuvalent stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $105.21, for a total value of $1,202,550.30. Following the completion of the sale, the chief financial officer directly owned 85,533 shares in the company, valued at approximately $8,998,926.93. The trade was a 11.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 126,953 shares of company stock valued at $12,612,264 in the last 90 days. 5.02% of the stock is currently owned by company insiders.

Institutional Trading of Nuvalent

A number of large investors have recently added to or reduced their stakes in NUVL. RA Capital Management L.P. bought a new stake in Nuvalent in the 3rd quarter worth approximately $107,794,000. Wellington Management Group LLP increased its stake in Nuvalent by 46.0% in the 3rd quarter. Wellington Management Group LLP now owns 2,300,865 shares of the company’s stock worth $198,979,000 after acquiring an additional 724,491 shares during the last quarter. Vanguard Group Inc. increased its stake in Nuvalent by 13.9% in the 4th quarter. Vanguard Group Inc. now owns 5,244,271 shares of the company’s stock worth $527,521,000 after acquiring an additional 639,264 shares during the last quarter. Norges Bank bought a new stake in Nuvalent in the 4th quarter worth approximately $57,763,000. Finally, JPMorgan Chase & Co. increased its stake in Nuvalent by 32.9% in the 4th quarter. JPMorgan Chase & Co. now owns 2,205,251 shares of the company’s stock worth $221,826,000 after acquiring an additional 545,542 shares during the last quarter. Institutional investors own 97.26% of the company’s stock.

More Nuvalent News

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK’s $10.6 billion all-cash acquisition offer gives Nuvalent shareholders a clear exit value at $124.00 per share, which is the biggest reason the stock has increased. Reuters article on GSK deal
• Positive Sentiment: Market commentary says the deal makes strategic sense for GSK because Nuvalent adds a late-stage oncology pipeline, supporting confidence that the transaction is credible and financially meaningful. MarketBeat analysis of the acquisition
• Neutral Sentiment: Several shareholder law firms have launched investigations into whether the sale process and price are fair, which could create headline noise but does not change the announced terms. Business Wire article on investigation
• Neutral Sentiment: Analyst downgrades followed the takeover news, but their revised price targets remain close to the deal value, so these moves are unlikely to outweigh the acquisition catalyst. Analyst downgrade coverage
• Negative Sentiment: CEO James Richard Porter sold 30,000 shares, a modest negative sentiment signal that may reinforce the view that insiders have been reducing exposure ahead of the transaction. SEC insider filing

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.